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E-mail address: seifert.roland@mh-hannover.de (RPhosphodiesterases (PDEs) capable of degrading cAMP and cGMP are indispensable for the regula-
tion of cyclic nucleotide-mediated signals. The existence of other cyclic nucleotides such as cCMP
and cUMP has been discussed controversially in the literature. Despite publications on PDEs hydro-
lyzing cCMP or cUMP, the molecular identity of such enzymes remained elusive. Recently, we have
provided evidence for a role of cCMP as second messenger in vascular relaxation and inhibition of
platelet aggregation. Using an HPLC–MS based assay, here, we show that human PDEs belonging to
various families hydrolyze not only cAMP and cGMP but also other cyclic nucleotides.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
cAMP and cGMP are well-established second messengers
involved in the regulation of numerous physiological functions
including heart contractility, smooth muscle relaxation and secre-
tion [1–3]. PDEs capable of degrading cNMPs are essential for the
regulation of the cNMP-mediated pathways by limiting the signals
in terms of time and space [2]. Human PDEs are divided into eleven
families that differ from each with respect to substrate- and tissue
speciﬁcity, biological function and regulation [3]. The natural
existence of the cyclic pyrimidine nucleotides cCMP and cUMP
has been discussed controversially in the literature [4–8] and
cCMP-mediated effects on neutrophil granulocytes were reported
[9]. Although data on PDEs hydrolyzing cCMP [10,11] and cUMP
[12,13] were also published, the molecular identity of such
enzymes has remained elusive so far. Recently, we have observed
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. Seifert).relaxation of vascular smooth muscle and platelet aggregation
[1]. These effects are mediated by cGMP-dependent protein kinase.
In the latter study, no functional evidence for hydrolysis of cCMP
by PDE5 was obtained. The renewed interest in cCMP prompted
us to investigate whether puriﬁed human PDEs are capable of
hydrolyzing other cNMPs than cAMP and cGMP, using an
HPLC–MS-based assay. HPLC–MS has already been successfully
applied to the determination of cAMP- and cGMP degradation by
PDEs [14]. As typical representatives, we examined human recom-
binant PDEs 1B, 2A, 3A, 3B, 4B, 5A, 8A and 9A.
2. Materials and methods
2.1. Materials
Partially puriﬁed human recombinant PDEs 1B (purity > 50%),
2A (purity > 70%), 3A (purity > 50%), 3B (purity > 70%), 4B (purity
70%), 5A (purity > 70%), 8A (purity > 70%) and 9A (purity > 80%)
were obtained from BPS Bioscience (San Diego, CA, USA). Detailed
information on the various enzyme preparations is provided on the
data sheets by BPS Bioscience. All PDEs were expressed in
Spodoptera frugiperda Sf9 insect cells. Sf9 cells are very well suited
for expression and puriﬁcation of recombinant PDEs because the
background of endogenous insect cell PDE activity is extremely
low [15]. Calmodulin was puriﬁed from calf brain [16]. AMP
sodium salt (>99%), CMP (>99%), GMP disodium salt (>98%), TMP
disodium salt (>99%), UMP disodium salt (>98%), IMP disodium saltlsevier B.V. All rights reserved.
Fig. 1. Linearity of cCMP detection via HPLC–MS. Areas under the curve of cCMP
peaks in MS were analyzed. The detected areas were normalized by means of the
internal standard Sp-cCMPS and plotted versus given cCMP concentrations of
0.078–10 lM. The insert shows a magniﬁcation of the lower concentrations (n = 3,
r2 = 0.9995).
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(Steinheim, Germany). cAMP sodium salt (>99%), cCMP sodium salt
(>98%), cGMP sodium salt (>98%), cIMP sodium salt (>98%), cTMP
sodium salt (>98%), cUMP sodium salt (>98%), cXMP sodium salt
(>98%) and Sp-cCMPS sodium salt (>98%) were obtained from Bio-
log Life Science Institute (Bremen, Germany). Solvents used in
HPLC analysis were water and acetonitrile (HPLC-gradient grade,
J.T. Baker, Deventer, The Netherlands). All other reagents were ana-
lytical grade.
2.2. PDE assay for HPLC–MS analysis
Using PDEs 2A, 3A, 3B, 4B, 8A and 9A the enzyme assay was per-
formed in a reaction buffer containing ﬁnal concentrations of
50 mM TRISHCl pH 7.5, 8.3 mM MgCl2 and 1.7 mM EDTA. For
quantifying PDE1B activity, 100 lM CaCl2, 100 lM EGTA and CaM
(100 nM) were added to the buffer. cAMP, cGMP, cCMP, cUMP,
cIMP, cXMP or cTMP were added at ﬁnal concentrations of
10 lM each. Reactions were initiated by adding the recombinant
enzymes at ﬁnal concentrations of 0.5 lg/ml (PDE1B), 0.65 lg/ml
(PDE2A), 0.7 lg/ml (PDE3A), 0.1125 lg/ml (PDE4B), 0.4 lg/ml
(PDE5A), or 1 lg/ml (PDE3B, PDE9A). Incubations were performed
at 25 C for 1 h or 24 h and were terminated by heating to 95 C for
5 min. Precipitates were sedimented by centrifugation at 4 C and
20,000g for 10 min. Forty microliters of the supernatant ﬂuid were
mixed with 40 ll of the internal standard solution (1 lM Sp-
cCMPS) and analyzed by HPLC–MS.
2.3. Quantitation of PDE reactions by HPLC–MS
The concentrations of cAMP, cGMP, cCMP, cUMP, cIMP, cXMP,
cTMP, AMP, GMP, CMP, UMP, IMP, XMP and TMP were determined
by a LC/MS system consisting of a binary HPLC pump for eluents A
and B (1100 Series, Agilent, Waldbronn, Germany) directly coupled
to a single quadrupole mass spectrometer (LC-MSD SL, Agilent)
operated in negative ion mode. A Hypercarb 30  4.6 mm 5 lm
column (ThermoFisher, Dreieich, Germany) equipped with a
column saver (2 lm, Supelco Analytical) and a C18 (ODS
Octadecyl) security guard (AJO-4286, Phenomenex) was used for
chromatography. Eluent A was 10 mM ammonium acetate
dissolved in HPLC-gradient grade water and calibrated to pH 10.0
with ammonium hydroxide, eluent B was acetonitrile. The injec-
tion volume was 50 ll per sample and the ﬂow rate was constantly
held at 0.4 ml/min. A linear gradient from 4% (v/v) B up to 60% (v/v)
B over 8 min was applied followed by an equilibration phase of
further 5 min at 4% (v/v) B. The following m/z [M-H] and reten-
tion times were found: cAMP: 328.1 Da, 8.2 min; cGMP:
344.1 Da, 7.6 min; cCMP: 304.1 Da, 6.5 min; cUMP: 305.1 Da,
6.1 min; cIMP: 329.1 Da, 6.6 min; cXMP: 345.1 Da, 6.1 min; cTMP:
303.1 Da, 7.3 min; AMP: 346.1 Da, 5.6 min; GMP: 362.1 Da,
5.4 min; CMP: 322.1 Da, 4.2 min; UMP: 323.1 Da, 4.1 min; IMP:
347.1 Da, 4.9 min; XMP: 363.0 Da, 4.5 min; TMP: 321.1 Da,
5.3 min; internal standard Sp-cCMPS: 320.1 Da, 7.2 min.
3. Results
The applied detection method allowed sensitive, speciﬁc and
quantitative detection of cNMP hydrolysis by PDEs. Fig. 1 shows
that the lower limit of quantitation of cCMP was <100 nmol/l ﬁnal
concentration. Limit of quantitation and linearity were similar for
the other cNMPs and also for the corresponding nucleoside
50-monophosphates being the reaction products (data not shown).
PDEs are classiﬁed according to their ability to hydrolyze cAMP
and cGMP. Based on Vmax, PDEs 3A, 3B and 4B exhibit a preference
for cAMP, and PDEs 1B and 5A possess a preference for cGMP [3].PDE2A hydrolyzes cAMP and cGMP with about equal efﬁcacy,
and PDE8A is cAMP-selective. PDE9A is classiﬁed as cGMP-prefer-
ring PDE [3,17,18]. For comparison of PDEs, we used a cNMP
substrate concentration of 10 lM each. In agreement with the
literature, we found that PDEs 3A, 3B and 4B hydrolyzed cAMP
more effectively than cGMP, PDE8A was cAMP-selective, PDEs 1B
and 5A showed the expected preference for cGMP, and PDE2A
cleaved cAMP and cGMP about equally well (Table 1). In contrast
to the literature [3,17,18], we did not observe preference of PDE9A
for cGMP (Table 1).
Strikingly, the PDEs studied exhibited a much broader sub-
strate-speciﬁcity than described in the literature so far [2,3]. PDE1B
did not only hydrolyze cAMP and cGMP but also cIMP and cXMP at
high rates (Tables 1 and 2). PDE2 hydrolyzed cIMP at similar rates
as cAMP and cGMP. PDE9A, PDE5A and the two isoforms of PDE3
were capable of degrading any tested cNMP, except for cCMP, at
differing rates. The 3-isobutyl-1-methylxanthine-insensitive
PDE8A was cAMP-speciﬁc, as shown in the literature [3,15]. The
cyclic pyrimidine nucleotides cUMP and cTMP were accepted as
substrates by several PDEs including PDE3A, PDE3B, PDE5A and
PDE9A, whereas no PDE was capable of hydrolyzing cCMP under
our experimental conditions.
In marked contrast to our present study, previous studies postu-
lated the existence of a cCMP-degrading PDE [10,11]. In order to
exclude the presence of a very low cCMP-degrading PDE activity
in our enzyme preparations, we extended the incubation time up
to 24 h (Table 2). Under these extreme conditions, cNMP hydroly-
sis by PDEs increased for cAMP, cGMP and cUMP, unless complete
turnover was already observed after one hour. In marked contrast,
even with the extremely extended incubation time, cCMP was not
degraded at all (Table 2).
4. Discussion
Using a sensitive and speciﬁc HPLC-MS method, here, we
conﬁrm the reported substrate-speciﬁcities of PDEs 1B, 2A, 3A,
3B, 4B, 5A and 8A for cAMP and cGMP (Table 1) [3]. In our study,
we examined commercially available and partially puriﬁed PDE
preparations. The PDEs were all expressed in Sf9 cells. Since the
background PDE activity in this system is very low [15], it is
very unlikely that contaminating insect cell enzyme activity
Table 1
cNMP degradation by puriﬁed human recombinant PDEs.
cNMP PDE1B PDE2A PDE3A PDE3B PDE4B PDE5A PDE8A PDE9A
cAMP 226 (195; 257) 30.1 ± 2.08 121 (83.0; 159) 162 (165; 158) 147 ± 9.92 219 ± 9.07 6.83 ± 0.22 30.5 ± 6.45
cGMP 326 ± 10.9 38.3 ± 8.62 20.3 (13.5; 27.1) 34.5 (39.0; 30.0) 66.6 ± 9.27 403 ± 20.1 n.d. 13.7 ± 4.30
cCMP n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
cUMP 9.60 ± 13.2 n.d. 102 (88.8; 114) 50.4 (58.9; 41.9) n.d. 18.7 (18.7; 18.8) n.d. 36.6 ± 6.21
cIMP 310 ± 38.6 29.8 ± 14.5 121 (97,3; 145) 165 (164; 166) 50.2 ± 10.9 415 ± 3.53 n.d. 26.7 ± 6.90
cXMP 159 (154; 164) 4.13 ± 1.68 24.6 (19.3; 29.9) 40.4 (46.0; 34.8) 3.33 ± 5.78 247 ± 53.1 n.d. 16.3 ± 5.40
cTMP n.d. n.d. 12.8 (13.7; 12.0) 4.65 (9.30; n.d) n.d. 71.2 ± 5.62 n.d. 14.0 ± 0.49
Degradation of various cNMPs by different PDEs was assessed. The initial concentration of each cNMP was 10 lmol/l, incubation time was one hour. Turnover was calculated
from the product concentrations detected via HPLC–MS after stopping the reaction. The activities are given as mean reaction rate in [nmol/mg/min]. n = 2–3, means ± SD or
means (single values), n.d. = not detected.
Table 2
cNMP hydrolysis by PDEs within different reaction times.
Incubation time (h) cAMP cGMP cCMP cUMP
PDE1B 1 67.9 (58.5; 77.3) 97.8 ± 3.29 n.d. 2.88 ± 3.97
24 99.4 ± 1.05 99.9 ± 0.12 n.d. 35.0 ± 3.30
PDE2A 1 11.8 ± 0.81 14.9 ± 3.36 n.d. n.d.
24 h 31.3 ± 15.2 27.9 ± 10.4 n.d. n.d.
PDE3A 1 50.8 (35.9; 67.8) 8.52 (5.68; 11.4) n.d. 42.7 (37.3; 48.0)
24 99.8 ± 0.39 39.2 ± 18.52 n.d. 96.2 ± 6.53
PDE4B 1 99.1 ± 0.67 4.49 ± 0.63 n.d. n.d.
24 100 ± 0.00 27.8 ± 1.67 n.d. 0.61 ± 0.33
PDE5A 1 52.7 ± 2.18 96.7 ± 4.82 n.d. 4.50 (4.48; 4.51)
24 89.9 ± 8.99 98.8 ± 1.74 n.d. 14.50 ± 5.48
PDE8A 1 4.10 ± 0.13 n.d. n.d. n.d.
24 57.7 ± 2.93 n.d. n.d. n.d.
PDE9A 1 18.3 ± 3.87 8.24 ± 2.58 n.d. 22.0 ± 3.73
24 66.4 ± 14.6 43.7 ± 5.25 n.d. 84.2 ± 10.0
cNMP hydrolysis by PDEs at different reaction times was assessed. The initial concentration of each cNMP was 10 lmol/l. Incubation times
were one hour and 24 h, respectively. Turnover is given in percent of the initial concentration and was calculated from the product concen-
trations measured via mass spectrometry. n = 2–3, means ± SD or means (single values), n.d. = not detected.
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hydrolysis by the aforementioned PDEs are congruent with lack
of contaminating PDE activity.
We used a substrate concentration of 10 lM for each cNMP.
With respect to cAMP ad cGMP, this concentration is in a physio-
logical range and, therefore, a good starting point for the analysis
of the substrate-speciﬁcity of PDEs [3]. The applied HPLC–MS
method allows for the analysis of the numerous cNMP substrates
that are not commercially available as radiolabeled compounds,
i.e. cIMP, cXMP, cCMP, cUMP and cTMP. Assaying a representative
spectrum of human PDEs from different families, we revealed that
these enzymes are, with the remarkable exception of the
cAMP-speciﬁc PDE8A, not speciﬁc for cAMP or cGMP. Rather, any
given PDE exhibits a unique substrate-speciﬁcity encompassing
cyclic purine and pyrimidine nucleotides. These data indicate that
the rather broad and yet unique substrate-speciﬁcity of PDEs does
not reﬂect ‘‘leakiness’’ but a hitherto unknown physiological
function of cyclic pyrimidine nucleotides.
In contrast to the cAMP- and cGMP preferences of the other
PDEs studied, for PDE9A we did not observe the predicted
cGMP-preference [3,17,18]. Among all PDEs examined, PDE9A
constituted the most pure enzyme (purity > 80%). As already
discussed above, contamination of recombinant PDEs with insect
cell PDE activity is very unlikely [15]. Rather, kinetic factors may
have confounded the cGMP-preference of PDE9A, i.e. after long
incubation times, cAMP hydrolysis of PDE9A may become more
signiﬁcant.
In this context, we would like to emphasize that the purpose of
our present study was not to present a precise kinetic analysis of
cNMP hydrolysis by PDEs. Rather, this study intends to provide a
ﬁrst survey on the unexpectedly broad substrate-speciﬁcities ofPDEs. In order to detect even low cNMP-hydrolytic activities, we
intentionally chose unusually long incubation times, well knowing
that these conditions did not ensure linearity of reaction velocities.
Moreover, long incubation times could (differentially) affect ther-
mostability of PDEs. For precise kinetic studies, that are subject
of future studies, much shorter incubation times and much lower
substrate concentrations will have to be examined. However, such
studies are not trivial since we will have to work with an expensive
high-end mass spectrometer ensuring much higher sensitivity
than the instrument used in our present experiments.
Previous studies claimed the existence of a cCMP-degrading
PDE [10,11]. However, we could not identify such activity among
a representative panel of human PDEs although these PDEs cleaved
other cyclic pyrimidine nucleotides than cCMP, speciﬁcally cUMP
and cTMP, quite effectively. In agreement with our present data,
Desch et al. [1] obtained no evidence for cleavage of cCMP by
PDE5A in functional experiments with smooth muscle cells. Of
course, our data do not exclude the existence of a speciﬁc
cCMP-degrading PDE. We have not yet studied all known human
PDE families.
Most intriguingly, the bacterial ‘‘adenylyl’’ cyclase toxins edema
factor from Bacillus anthracis and CyaA from Bordetella pertussis
also possess low but clearly detectable cytidylyl cyclase activity,
giving rise to the production of cCMP [19]. If cCMP is not degraded
by PDEs, then even with low catalytic cytidylyl cyclase activity, a
substantial accumulation of cCMP could occur, resulting in toxic
cellular effects. In fact, the cytotoxic effects of edema factor cannot
be sufﬁciently explained by cAMP accumulation alone [20].
Hardman et al. [13] described a cUMP-degrading PDE activity in
homogenates from beef and dog heart. This is consistent with the
high cUMP turnover by puriﬁed PDE3A since PDE3A is present in
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cUMP. Klotz and Stock’s [12] report of a cUMP-hydrolyzing PDE
activity in rat adipose tissue supports our ﬁndings in view of the
fact that PDE3B is expressed in adipocytes [22]. These data suggest
that cUMP could play a role in the regulation of heart function and
lipolysis. PDE9A, a widely expressed PDE [3], appears to exhibit
preference for cUMP. In the papers reporting PDE9A cloning and
initial biochemical characterization, cUMP was not tested as
potential substrate [17,18]. Collectively, our data could point to a
more general (patho)physiological role of cUMP.
In conclusion, taking advantage of a sensitive and speciﬁc
HPLC–MSmethod, we have found that several human PDEs possess
a much broader substrate-speciﬁcity than previously assumed.
Based on our data, a systematic re-analysis of the substrate-
speciﬁcities of all human PDEs is urgently required. Moreover,
our data call for the determination of the concentrations of cIMP,
cXMP, cCMP, cUMP and cTMP in cells and organs. For both types
of studies, highly sensitive mass spectrometry methods are
required. Perhaps, the second messenger function of cNMPs goes
beyond cAMP and cGMP [2,3,23–25].
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